MAR 2 6 200

Atty Docket No. 021911-000600US

PTO FAX NO.:

(703) 872-9306

ATTENTION:

TELEPHONE NO.:

Examiner Celine X. Qian

Group Art Unit 1636

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER Celine X. Qian

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document(s)in re Application of Claire E. Lewis, et al., Application No. 09/284,009, filed April 5, 1999 for MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

- 1. Supplemental Response Under 37 C.F.R. §1.111
- 2. Declaration Under 37 C.F.R. §1.132 By Stuart Naylor, Ph.D., with attachment

Number of pages being transmitted, including this page: 23

Dated: March 26, 2004

PLEASE CONFIRM RECEIPT OF THIS PAPER BY *RETURN FACSIMILE AT (415) 576-0300*

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, CA 94111-3834 Telephone: 858-350-6100

Fax: 858-350-6111

CENTRAL FAX CENTER

MAR 2 6 200

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office,

Fax No. :1-703-872-9306 on March 26, 2004

Attorney Docket No.: 021911-000600US

Client Ref. No.: OBM15

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

C. Qian

Lewis, et al.

Art Unit:

1636

Application No.: 09/284,009

Filed: April 5, 1999

<u>SUPPLEMENTAL RESPONSE UNDER</u> <u>37 C.F.R.. § 1.111</u>

For: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Further to the Response and Amendment mailed Monday, March 22, 2004, this Supplemental Response 1) corrects an inadvertent error in the presentation of the listing of claims and 2) presents a copy of the second declaration under 37 C.F.R. § 1.132 as executed by Dr. Stuart Naylor.

As the Response of March 22, 2004 was fully responsive to the Office Action mailed December 21, 2003, no fee is believed necessary for the instant Supplemental Response.

The listing of the pending claims begins on page 2 of this paper.

Remarks begin on page 6 of this paper.